Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies

Abstract Oncogenic BRAF mutations, including those in non-small cell lung cancer (NSCLC), are classified as Class I, II, or III. While approved therapies exist for BRAF Class I mutants, no approved therapies exist for Class II and III BRAF-mutated NSCLC. Analysis of a circulating tumor DNA database...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Tadashi Manabe, Hannah C. Bergo, Qingtian Li, Tim Sen Wang, Paul Severson, Nichol Miller, Catherine Lee, Elifnur Yay Donderici, Nicole Zhang, Wei Wu, Yu-Ting Chou, Daniel L. Kerr, Paul Allegakoen, Kathryn B. Grandinetti, Liliana Soroceanu, Robert J. Pelham, Eric S. Martin, Eric A. Murphy, Vishesh Khanna, Joel W. Neal, Christopher T. Chen, Shumei Kato, Richard Williams, Trever G. Bivona
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Nature Portfolio 2026-02-01
coleção:	Nature Communications
Acesso em linha:	https://doi.org/10.1038/s41467-026-69216-3
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!